Marc Debled

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Thomas Bachelot, C. Bourgier, Claire Cropet et al. · Journal of Clinical Oncology · 2012 · 709 citations · Full text

Medicine, Oncology, Pharmacology +17

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Prudence A. Francis, Olivia Pagani, Gini F. Fleming et al. · New England Journal of Medicine · 2018 · 673 citations · Full text

Medicine, Endocrinology, Oncology +17

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up

L. Mauriac, Gaëtan MacGrogan, A. Avril et al. · Annals of Oncology · 1999 · 441 citations · Full text

Medicine, Oncology, Breast Oncology +13

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer

Carine Bellera, Gaëtan MacGrogan, Marc Debled et al. · BMC Medical Research Methodology · 2010 · 381 citations · Full text

Medicine, Biostatistics, Oncology +16